The DOI matches its Crossref record; 134 of the 134 references it cites were found in a registry or an index.
Epidemiology and Management of Hepatocellular Carcinoma
Open accessAbstract
The major risk factors for hepatocellular carcinoma (HCC) in a contemporary clinical practice is becoming increasingly related to post sustained virological response hepatitis C, suppressed hepatitis B virus on treatment, alcoholic and non-alcoholic fatty liver disease. We review the emerging data on the risk and determinants of HCC in these conditions, and the implications to HCC surveillance. However, from a public health perspective, active hepatitis C and B continue to drive most of the global burden of HCC. In United States, the age adjusted incidence rates of HCC in Hispanics have surpassed that of Asians. Prognosis in HCC is complex due to the competing risk imposed by underlying cirrhosis and presence of malignancy. In addition to tumor burden, liver function and performance status, additional parameters including tumor biopsy, serum markers and sub classification of current staging systems, taking into account patterns of tumor progression, may improve patient selection for therapy. Advancements in the treatment of HCC has included identification of patients that are most likely to derive a clinically significant benefit from the available therapeutic options. Additionally, the combination strategies of locoregional therapies and/or systemic therapy are being investigated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406
Management of Hepatocellular Carcinoma: An Update Δσ
Bruix, J., & Sherman, M. (2011) · Hepatology · doi:10.1002/hep.24199 · Cited by 8,103
A New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib
Kudo, M. (2017) · Liver Cancer · doi:10.1159/000462153 · Cited by 5,936
Sorafenib in Advanced Hepatocellular Carcinoma
정, 재. (2008) · Cited by 5,586
Kudo, M., Finn, R. S., Qin, S., Han, K.-H., Ikeda, K., Piscaglia, F., Baron, A., Park, J.-W., Han, G., Jassem, J., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30207-1 · Cited by 5,497
EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
European Association for the Study of the Liver, & European Organisation for Research and Treatment of Cancer (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.12.001 · Cited by 5,218
Marrero, J. A., Kulik, L. M., Sirlin, C. B., Zhu, A. X., Finn, R. S., Abecassis, M. M., Roberts, L. R., & Heimbach, J. K. (2018) · Hepatology · doi:10.1002/hep.29913 · Cited by 4,539
Self-citationEl-Khoueiry, A. B., Sangro, B., Yau, T., Crocenzi, T. S., Kudo, M., Hsu, C., Kim, T.-Y., Choo, S.-P., Trojan, J., Welling, T. H., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31046-2 · Cited by 4,280
AASLD guidelines for the treatment of hepatocellular carcinoma
Heimbach, J. K., Kulik, L. M., Finn, R. S., Sirlin, C. B., Abecassis, M. M., Roberts, L. R., Zhu, A. X., Murad, M. H., & Marrero, J. A. (2018) · Hepatology · doi:10.1002/hep.29086 · Cited by 4,070
Self-citation
Cited by
Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma
Llovet, J. M., De Baere, T., Kulik, L., Haber, P. K., Greten, T. F., Meyer, T., & Lencioni, R. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00395-0 · Cited by 1,044
Self-citationHepatocellular carcinoma (HCC): Epidemiology, etiology and molecular classification
(2021) · Advances in Cancer Research · doi:10.1016/bs.acr.2020.10.001 · Cited by 851
Paik, J. M., Golabi, P., Younossi, Y., Mishra, A., & Younossi, Z. M. (2020) · Hepatology · doi:10.1002/hep.31173 · Cited by 788
Current status and future trends of the global burden of MASLD
Miao, L., Targher, G., Byrne, C. D., Cao, Y.-Y., & Zheng, M.-H. (2024) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2024.02.007 · Cited by 781
The gut–liver axis and gut microbiota in health and liver disease
Hsu, C. L., & Schnabl, B. (2023) · Nature Reviews Microbiology · doi:10.1038/s41579-023-00904-3 · Cited by 737
Milosevic, I., Vujovic, A., Barac, A., Djelic, M., Korac, M., Radovanovic Spurnic, A., Gmizic, I., Stevanovic, O., Djordjevic, V., Lekic, N., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20020395 · Cited by 551
Kelley, R. K., Rimassa, L., Cheng, A.-L., Kaseb, A., Qin, S., Zhu, A. X., Chan, S. L., Melkadze, T., Sukeepaisarnjaroen, W., Breder, V., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00326-6 · Cited by 535
Mechanisms of liver fibrosis and its role in liver cancer
Dhar, D., Baglieri, J., Kisseleva, T., & Brenner, D. A. (2020) · Experimental Biology and Medicine · doi:10.1177/1535370219898141 · Cited by 429
Loomba, R., Lim, J. K., Patton, H., & El-Serag, H. B. (2020) · Gastroenterology · doi:10.1053/j.gastro.2019.12.053 · Cited by 357
Self-citationCirculating biomarkers in the diagnosis and management of hepatocellular carcinoma
Johnson, P., Zhou, Q., Dao, D. Y., & Lo, Y. M. D. (2022) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-022-00620-y · Cited by 320
Liver homeostasis is maintained by midlobular zone 2 hepatocytes
Wei, Y., Wang, Y. G., Jia, Y., Li, L., Yoon, J., Zhang, S., Wang, Z., Zhang, Y., Zhu, M., Sharma, T., et al. (2021) · Science · doi:10.1126/science.abb1625 · Cited by 292
Current epidemiology in hepatocellular carcinoma
Konyn, P., Ahmed, A., & Kim, D. (2021) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2021.1991792 · Cited by 280
Immunomodulatory TGF-β Signaling in Hepatocellular Carcinoma
Chen, J., Gingold, J. A., & Su, X. (2019) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2019.06.007 · Cited by 260
Somatic Mutations Increase Hepatic Clonal Fitness and Regeneration in Chronic Liver Disease
Zhu, M., Lu, T., Jia, Y., Luo, X., Gopal, P., Li, L., Odewole, M., Renteria, V., Singal, A. G., Jang, Y., et al. (2019) · Cell · doi:10.1016/j.cell.2019.03.026 · Cited by 250
“The common pathological endpoint for these diverse processes is endstage liver fibrosis, also known as cirrhosis, which affects up to 1%of the population and is a critical risk factor for hepatocellular carcinoma (HCC) (Kulik and El-Serag, 2019).”
BackgroundLeFort, K. R., Rungratanawanich, W., & Song, B.-J. (2024) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-023-05061-7 · Cited by 202
“HCC is highly associated with metabolic risk factors and alcohol consumption [323], and is exacerbated by underlying cirrhosis [324].”
BackgroundLonardo, A., & Suzuki, A. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9051278 · Cited by 129
“NAFLD covers the clinico-pathological gamut including uncomplicated steatosis, steatohepatitis, which is steatosis accompanied by hepatocyte damage and inflammation, cirrhosis and hepatocellular carcinoma (HCC).”
BackgroundInfluentialLi, Y.-M., Xu, C., Sun, B., Zhong, F.-J., Cao, M., & Yang, L.-Y. (2022) · Cancer Cell International · doi:10.1186/s12935-022-02574-2 · Cited by 52
Lipid droplets disrupt mechanosensing in human hepatocytes
Chin, L., Theise, N. D., Loneker, A. E., Janmey, P. A., & Wells, R. G. (2020) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00098.2020 · Cited by 38
CHEK2 knockout is a therapeutic target for TP53-mutated hepatocellular carcinoma
Chen, Y., Zhu, Z., Wu, X., Li, H., Guan, W., & Ren, H. (2024) · Cell Death Discovery · doi:10.1038/s41420-023-01777-4 · Cited by 6
“The study utilized publicly available data from a comprehensive genome-wide association study on blood expression, which can be found at the page (https://eqtlgen.org/cis-eqtls.html).”
Method
Metadata
- Authors
- Kulik, L., & El-Serag, H. B.
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 2019-01
- Volume
- 156
- Issue
- 2
- Pages
- 477-491.e1
- ISSN
- 0016-5085 (ISSN-L)
- OpenAlex
- W2898314774
- Cited by
- 1,735
- References
- 134
- FWCI
- 82.94
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.